The Safety and Effects of Bosentan in Patients with a Fontan Circulation

Congenital Heart Disease

Volumn 7, Issue 3, 2012, Pages 243-249

  Bowater, Sarah E ^a   Weaver, Rebekah A ^a   Thorne, Sara A ^a   Clift, Paul F ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bosentan; Cardiac output; Fontan; Pulmonary vascular resistance; Safety

Indexed keywords

BOSENTAN;

ADULT; ARTICLE; BORG DYSPNEA INDEX; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FONTAN CIRCULATION; FONTAN PROCEDURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

ADULT; CARDIOVASCULAR AGENTS; ECHOCARDIOGRAPHY, DOPPLER; ENGLAND; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HUMANS; MALE; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN; RECOVERY OF FUNCTION; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE; VENTRICULAR FUNCTION;

EID: 84861536976     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2012.00635.x     Document Type: Article

References (20)

1. Driscoll DJ, Offord KP, Feldt RH, Schaff HV, Puga FJ, Danielson GK. Five- to fifteen-year follow-up after Fontan operation. Circulation. 1992;85:469-496.
2. Diller GP, Giardini A, Dimopoulos K, etal. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J. 2010;31:3073-3078.
3. Gewillig M, Brown SC, Eyskens B, etal. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 2010;10:428-433.
4. Goldstein BH, Connor CE, Gooding L, Rocchini CP. Relation of systemic venous return, pulmonary vascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving Fontan palliation. Am J Cardiol. 2010;105:1169-1175.
5. Mitchell MB, Campbell DN, Ivy D, etal. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg. 2004;128:693-702.
6. Schuuring MJ, Vis JC, Mouma BJ, etal. Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity? Contemp Clin Trials. 2011;32:586-591.
7. Goldberg DJ, French B, McBride MG, etal. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123:1185-1193.
8. Galiè N, Hoeper MM, Humbert M, etal. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.
9. Channick RN, Simonneau G, Sitbon O, etal. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
10. Rubin LJ, Badesch DB, Barst RJ, etal. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
11. Galiè N, Rubin L, Hoeper M, etal. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093-2100.
12. Barst RJ, Ivy D, Dingemanse J, etal. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-382.
13. Beghetti M. Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies. Heart. 2010;96:911-916.
14. Actelion Pharmaceuticals Ltd. Tracleer (bosentan) Summary of Product Characteristics. Available at:. Accessed August 17, 2011.
15. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant. 2005;24:1174-1176.
16. Ovaert C, Thijs D, Dewolf D, etal. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19:331-339.
17. Hirono K, Yoshimura N, Taguchi M, etal. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiovasc Surg. 2010;140:346-351.
18. O'Donnell DE, Sciurba F, Celli B, etal. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647-656.
19. Travers J, Laveneziana P, Webb KA, Kesten S, O'Donnell DE. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med. 2007;101:2017-2024.
20. Marino BS, Tomlinson RS, Wernovsky G, etal. Pediatric cardiac quality of life inventory testing study consortium. Validation of the pediatric cardiac quality of life inventory. Pediatrics. 2010;126:498-508.